Quantum-Si (QSI) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
14 Jan, 2026Executive summary
Q3 2024 revenue reached $787,000, up 252.9% year-over-year, driven by the Platinum instrument launch and commercial ramp-up.
Gross profit for Q3 2024 was $367,000 with a gross margin of 47%.
Net loss for Q3 2024 was $25.3 million, compared to $24.7 million in Q3 2023; nine-month net loss was $67.9 million, improved from $73.9 million year-over-year.
Cash, cash equivalents, and marketable securities totaled $196.3 million as of September 30, 2024, expected to fund operations into the second half of 2026.
Leadership strengthened with new CCO, CPO, and CHRO appointments, and ongoing innovation recognized by industry awards.
Financial highlights
Product revenue grew 253.7% year-over-year in Q3 2024, while service revenue increased 228.6%.
Gross margin for Q3 2024 was 47%, impacted by inventory carried at low or no value.
Adjusted operating expenses for Q3 2024 were $26 million, up from $23.9 million in Q3 2023; GAAP operating expenses were $28.5 million.
Adjusted EBITDA for Q3 2024 was negative $24.5 million.
Cash used in operating activities was $64.9 million for the nine months ended September 30, 2024.
Outlook and guidance
Sequential revenue increase expected in Q4 2024, with confidence in surpassing $1 million in quarterly revenue for the first time.
Full-year 2024 revenue is expected to fall short of the $3.7–$4.2 million guidance due to lengthening sales cycles.
Adjusted operating expenses for 2024 projected at ~$100 million, with net cash usage of ~$92 million.
Cash runway projected into the second half of 2026.
May seek additional financing if revenue growth does not meet expectations.
Latest events from Quantum-Si
- 2026 emphasizes consumables growth and Proteus launch, with strong cash reserves and cost control.QSI
Q4 20253 Mar 2026 - Q2 2024 revenue rose 203% to $622,000, with a 57% margin and cash runway into 2026.QSI
Q2 20242 Feb 2026 - Rapid innovation and commercial expansion position the platform for strong growth in proteomics.QSI
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Automated protein sequencing platform drives adoption and innovation across research sectors.QSI
H.C. Wainwright 26th Annual Global Investment Conference21 Jan 2026 - Proteus and Platinum Pro launch drive scalable, automated, and versatile proteomics workflows.QSI
Investor Day 202413 Jan 2026 - Q4 revenue up 52% sequentially, 183% YoY, $86M raised, and cash runway into 2027.QSI
Q4 202424 Dec 2025 - Up to $300M in securities may be offered, with $100M via at-the-market sales through Leerink Partners.QSI
Registration Filing16 Dec 2025 - Up to $300M in securities, including $100M at-the-market stock, to fund growth amid notable risks.QSI
Registration Filing16 Dec 2025 - Annual meeting to vote on directors, auditor, and executive pay; board remains majority-independent.QSI
Proxy Filing1 Dec 2025